

31 March 2023

Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")

Exercise of Options & Issue of Equity

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, announces that pursuant to the exercise of options at nil cost under the Inspiration Healthcare Group plc Long Term Incentive Plan (the "LTIP") by certain employees of the Group, a total of 104,196 new ordinary shares of 10p each ("New Ordinary Shares") have been allotted and issued by the Company.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and such Admission is expected to become effective at 8.00am on 5 April 2023. The New Ordinary Shares shall rank pari passu with the existing Ordinary Shares in issue.

Total Voting Rights

Following the above issue of New Ordinary Shares, the issued share capital of the Company will comprise 68,234,802 Ordinary Shares, with no Ordinary Shares held in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure, Guidance and Transparency Rules.

For further information:

Inspiration Healthcare Group plc

Tel: +44 (0)330 175 0000

Neil Campbell, Chief Executive Officer

Cenkos Securities plc (Nominated Adviser & Broker)

Tel: +44 (0)207 397 8900

Stephen Keys, Katy Birkin, Dan Hodgkinson

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780

Anna Dunphy/Stephanie Cuthbert

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

The Company has key own brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.

Since September 2019, the Company has acquired Vio Holdings a designer, manufacturer and supplier of single use respiratory products and sterile medical consumables and S.L.E., a leading designer, manufacturer and global provider of neonatal ventilation products. The Group generates approximately 58% of its revenues from export markets and more than half of its revenues come from its own-branded products.

With product availability actively promoted to over 80 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent

commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland, the Group has direct sales teams selling Group Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

The Group operates from various sites in the UK for R&D, Marketing and operations with manufacturing based in Croydon (south London) and Hailsham (East Sussex). The Group's Head Office is located in Crawley, a short distance from London's Gatwick Airport.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDFLFXXXLLBBQ